Lipocine (NASDAQ:LPCN) posted its quarterly earnings results on Monday. The specialty pharmaceutical company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.04), Yahoo Finance reports.

Lipocine (LPCN) opened at $1.48 on Wednesday. Lipocine has a 1-year low of $1.15 and a 1-year high of $5.33.

How to Become a New Pot Stock Millionaire

Several analysts have recently commented on LPCN shares. HC Wainwright set a $3.00 price target on Lipocine and gave the company a “buy” rating in a report on Friday, January 12th. Canaccord Genuity reissued a “hold” rating and issued a $2.00 price target (down from $11.00) on shares of Lipocine in a report on Tuesday, January 9th. Finally, Ladenburg Thalmann Financial Services reissued a “buy” rating and issued a $11.00 price target on shares of Lipocine in a report on Thursday, January 11th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. Lipocine has an average rating of “Hold” and an average target price of $13.50.

COPYRIGHT VIOLATION NOTICE: This story was first posted by Daily Political and is the property of of Daily Political. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.dailypolitical.com/2018/03/14/lipocine-lpcn-releases-quarterly-earnings-results-misses-expectations-by-0-04-eps.html.

Lipocine Company Profile

Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.

Earnings History for Lipocine (NASDAQ:LPCN)

Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.